Chemotherapy Induced Neutropenia Drugs Market 2032: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Therapies, Statistics, Revenue, Patient Pool, Prevalence and Companies DelveInsight

(Albany, USA) DelveInsight's "Chemotherapy Induced Neutropenia Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Chemotherapy Induced Neutropenia, historical and forecasted epidemiology as well as the Chemotherapy Induced Neutropenia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The Chemotherapy Induced Neutropenia market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Chemotherapy Induced Neutropenia treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Chemotherapy Induced Neutropenia market.

To Know in detail about the Chemotherapy Induced Neutropenia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chemotherapy Induced Neutropenia Market Forecast - https://www.delveinsight.com/sample-request/chemotherapy-induced-neutropenia-cin-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key facts of the Chemotherapy Induced Neutropenia Market Report:
• The Chemotherapy Induced Neutropenia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In the 7MM, there were around 1,816,200 cancer patients receiving chemotherapy as of 2021.In 2021, the US accounted for the largest number of cancer patients receiving chemotherapy, with around 705,300 cases. Japan has about 322,300 cancer patients receiving chemotherapy in 2021, placing it second out of 7MM countries
• In 2021, there were approximately 167,000 cancer patients receiving chemotherapy in the UK. It is anticipated that the number of these instances will rise during the projection period
• that in Germany in 2021, there were around 63,000 cases at low risk for CIN and approximately 147,000 cases at intermediate-high risk
• With approximately 97,800 occurrences of CIN in 2021, Germany had the greatest number of cases within the EU4. However, with just about 46,800 cases, Spain had the fewest CIN cases in 2021
• Key Chemotherapy Induced Neutropenia Companies: Enzychem Lifesciences Corporation, Aileron Therapeutics, Evive Biotech, Myelo therapeutics, BeyondSpring Pharmaceuticals, BeyondSpring Pharmaceuticals, Dong-A ST Co., Ltd., Tianjin SinoBiotech Ltd., Biocad, Tianjin SinoBiotech Ltd., Teva Branded Pharma, Sandoz GmbH, Kyowa Kirin Co., Ltd., Prothya Biosolutions, and others
• Key Chemotherapy Induced Neutropenia Therapies: EC-18, ALRN-6924, F-627 (Ryzneuta), Myelo001, Plinabulin, Pegfilgrastim, PEG-G-CSF, rHSA-GCSF 2.4mg, empegfilrastim, HSA-GCSF, Chemotherapy Regimen, LA-EP2006, pegfilgrastim, Mannan Binding Lectin (MBL), and others
• The Chemotherapy Induced Neutropenia epidemiology based on gender analyzed that out of the total patients on chemotherapy, maximum patients are at intermediate-high risk for CIN
• The Chemotherapy Induced Neutropenia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chemotherapy Induced Neutropenia pipeline products will significantly revolutionize the Chemotherapy Induced Neutropenia market dynamics.
• In June 2025, Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that data from the BEAT AML trial of revumenib in combination with venetoclax and azacitidine (ven/aza) in newly diagnosed mutant NPM1 (mNPM1) and KMT2A-rearranged (KMT2Ar) acute myeloid leukemia (AML) patients were published in the Journal of Clinical Oncology and simultaneously presented in an oral session at the 30th European Hematology Association (EHA) Annual Congress Meeting being held June 12-15, 2025, in Milan, Italy and virtually.
• Phase III results for 8MW0511, a novel G‐CSF fusion protein delivered once per chemotherapy cycle, were published on May 6, 2025, showing non‐inferiority to PEG‐rhG‐CSF in breast cancer patients receiving TC/TAC chemotherapy.
• A Phase III trial of telpegfilgrastim in non‐small cell lung cancer was published on March 17, 2025, demonstrating non‐inferior efficacy in reducing grade 4 neutropenia compared to rhG‐CSF or PEG‐rhG‐CSF in four chemotherapy cycles.
• The Guard‐02 study of efbemalenograstim alfa released interim data in early 2025, confirming safety and efficacy in prophylactic CIN treatment with a single 20 mg dose.
• In August 2024, Tanvex BioPharma USA, Inc., a contract development and manufacturing organization (CDMO) for biologics and a biosimilars products company, has received U.S. FDA approval for Nypozi (filgrastim-txid), the company's biosimilar referencing Neupogen,1, to treat chemotherapy-induced neutropenia in cancer patients. The approval marks an important regulatory milestone that was quickly complemented by the FDA's acceptance of the company's Biologics License Application (BLA) for TX-05, an investigational antineoplastic biologic targeting HER2-positive breast and gastric cancer, a proposed biosimilar to Herceptin,2 (trastuzumab).
• On November 16, 2023, the US Food and Drug Administration (FDA) approved Ryzneuta (efbemalenograstim alfa-vuxw), a novel long-acting granulocyte colony-stimulating factor (G-CSF), for the prevention and treatment of febrile neutropenia in adults with nonmyeloid malignancies receiving myelosuppressive chemotherapy.

Chemotherapy Induced Neutropenia Overview
Chemotherapy-Induced Neutropenia (CIN) is a common and potentially serious complication arising from cancer treatment. Neutropenia refers to an abnormally low count of neutrophils, a type of white blood cell vital for fighting infections. Chemotherapy targets rapidly dividing cells, which includes not only cancer cells but also healthy cells in the bone marrow responsible for producing neutrophils. As a result, patients undergoing chemotherapy often experience a drop in their white blood cell count, leading to neutropenia.

Chemotherapy-Induced Neutropenia significantly increases a patient's risk of infections, which can range from mild to life-threatening, particularly in cases of febrile neutropenia - neutropenia accompanied by fever. This condition often necessitates hospitalization and can disrupt chemotherapy schedules, potentially impacting the overall effectiveness of cancer treatment. The risk and severity of Chemotherapy-Induced Neutropenia depend on factors such as the type of chemotherapy regimen, cancer type, patient age, and pre-existing health conditions.

To manage and prevent Chemotherapy-Induced Neutropenia, oncologists may adjust chemotherapy doses, delay treatment, or prescribe supportive therapies such as granulocyte colony-stimulating factors (G-CSFs). These agents stimulate the bone marrow to produce more neutrophils, reducing the duration and severity of neutropenia. Ongoing research is also focused on novel agents to enhance patient safety and treatment outcomes.

Get a Free sample for the Chemotherapy Induced Neutropenia Market Report
https://www.delveinsight.com/report-store/chemotherapy-induced-neutropenia-cin-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Chemotherapy Induced Neutropenia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Chemotherapy Induced Neutropenia Epidemiology Segmentation:
The Chemotherapy Induced Neutropenia market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Chemotherapy Induced Neutropenia
• Prevalent Cases of Chemotherapy Induced Neutropenia by severity
• Gender-specific Prevalence of Chemotherapy Induced Neutropenia
• Diagnosed Cases of Episodic and Chronic Chemotherapy Induced Neutropenia

Download the report to understand which factors are driving Chemotherapy Induced Neutropenia epidemiology trends @ Chemotherapy Induced Neutropenia Epidemiology Forecast
https://www.delveinsight.com/sample-request/chemotherapy-induced-neutropenia-cin-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Chemotherapy Induced Neutropenia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chemotherapy Induced Neutropenia market or expected to get launched during the study period. The analysis covers Chemotherapy Induced Neutropenia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Chemotherapy Induced Neutropenia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Chemotherapy Induced Neutropenia Therapies and Key Companies
• EC-18: Enzychem Lifesciences Corporation
• ALRN-6924: Aileron Therapeutics
• F-627 (Ryzneuta): Evive Biotech
• Myelo001: Myelo therapeutics
• Plinabulin: BeyondSpring Pharmaceuticals
• Pegfilgrastim: BeyondSpring Pharmaceuticals
• PEG-G-CSF: Dong-A ST Co., Ltd.
• rHSA-GCSF 2.4mg: Tianjin SinoBiotech Ltd.
• empegfilrastim: Biocad
• HSA-GCSF: Tianjin SinoBiotech Ltd.
• Chemotherapy Regimen: Teva Branded Pharma
• LA-EP2006: Sandoz GmbH
• pegfilgrastim: Kyowa Kirin Co., Ltd.
• Mannan Binding Lectin (MBL): Prothya Biosolutions

Discover more about therapies set to grab major Chemotherapy Induced Neutropenia market share @ Chemotherapy Induced Neutropenia Treatment Market - https://www.delveinsight.com/sample-request/chemotherapy-induced-neutropenia-cin-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Chemotherapy Induced Neutropenia Market Strengths
• The growth in the cancer patient population, along with a rise in the comorbidities and use of certain drugs (chemotherapies) over the globe, is contributing to the rise in the incidence of CIN
• An increase in clinical trials activity for emerging therapies will boost the market
• Rising awareness about the disease among clinicians and patients

Chemotherapy Induced Neutropenia Market Opportunities
• Limited development in the mechanism of action of approved therapies in the market offers a great opportunity for the investment and development of emerging novel therapies
• Medications with better safety for long term use and low treatment duration are the current unmet need of the CIN market
• Low-cost therapies and therapies with good patient compliance might be the game-changer for the CIN treatment market

Scope of the Chemotherapy Induced Neutropenia Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Chemotherapy Induced Neutropenia Companies: Enzychem Lifesciences Corporation (183490: KRX), Aileron Therapeutics (ALRN: NASDAQ), Evive Biotech (Privately Held), Myelo Therapeutics (Privately Held), BeyondSpring Pharmaceuticals (BYSI: NASDAQ), Dong-A ST Co., Ltd. (170900: KRX), Tianjin SinoBiotech Ltd. (Privately Held), Biocad (Privately Held), Teva Branded Pharma (TEVA: NYSE), Sandoz GmbH (SDZ: SIX), Kyowa Kirin Co., Ltd. (4151: TYO), Prothya Biosolutions, and others
• Key Chemotherapy Induced Neutropenia Therapies: EC-18, ALRN-6924, F-627 (Ryzneuta), Myelo001, Plinabulin, Pegfilgrastim, PEG-G-CSF, rHSA-GCSF 2.4mg, empegfilrastim, HSA-GCSF, Chemotherapy Regimen, LA-EP2006, pegfilgrastim, Mannan Binding Lectin (MBL), and others
• Chemotherapy Induced Neutropenia Therapeutic Assessment: Chemotherapy Induced Neutropenia current marketed and Chemotherapy Induced Neutropenia emerging therapies
• Chemotherapy Induced Neutropenia Market Dynamics: Chemotherapy Induced Neutropenia market drivers and Chemotherapy Induced Neutropenia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Chemotherapy Induced Neutropenia Unmet Needs, KOL's views, Analyst's views, Chemotherapy Induced Neutropenia Market Access and Reimbursement

To know more about Chemotherapy Induced Neutropenia companies working in the treatment market, visit @ Chemotherapy Induced Neutropenia Clinical Trials and Therapeutic Assessment - https://www.delveinsight.com/sample-request/chemotherapy-induced-neutropenia-cin-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Chemotherapy Induced Neutropenia Market Report Introduction
2. Executive Summary for Chemotherapy Induced Neutropenia
3. SWOT analysis of Chemotherapy Induced Neutropenia
4. Chemotherapy Induced Neutropenia Patient Share (%) Overview at a Glance
5. Chemotherapy Induced Neutropenia Market Overview at a Glance
6. Chemotherapy Induced Neutropenia Disease Background and Overview
7. Chemotherapy Induced Neutropenia Epidemiology and Patient Population
8. Country-Specific Patient Population of Chemotherapy Induced Neutropenia
9. Chemotherapy Induced Neutropenia Current Treatment and Medical Practices
10. Chemotherapy Induced Neutropenia Unmet Needs
11. Chemotherapy Induced Neutropenia Emerging Therapies
12. Chemotherapy Induced Neutropenia Market Outlook
13. Country-Wise Chemotherapy Induced Neutropenia Market Analysis (2019-2032)
14. Chemotherapy Induced Neutropenia Market Access and Reimbursement of Therapies
15. Chemotherapy Induced Neutropenia Market Drivers
16. Chemotherapy Induced Neutropenia Market Barriers
17. Chemotherapy Induced Neutropenia Appendix
18. Chemotherapy Induced Neutropenia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Trending Reports:
• Angina Pectoris Market: https://www.delveinsight.com/report-store/angina-angina-pectoris-market
• Anorectal Malformation Market: https://www.delveinsight.com/report-store/anorectal-malformation-market
• Anovulation Market: https://www.delveinsight.com/report-store/anovulation-market
• Anterior Cruciate Ligament Injuries Market: https://www.delveinsight.com/report-store/anterior-cruciate-ligament-injuries-epidemiology-forecast
• Antibody Mediated Rejection Market: https://www.delveinsight.com/report-store/antibody-mediated-rejection-market
• Antiphospholipid Syndrome Aps Market: https://www.delveinsight.com/report-store/antiphospholipid-syndrome-aps-market
• Arthroscopic Shavers Market: https://www.delveinsight.com/report-store/arthroscopic-shavers-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Aspergillosis Market: https://www.delveinsight.com/report-store/aspergillosis-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Atypical Teratoid Rhabdoid Tumors Market: https://www.delveinsight.com/report-store/atypical-teratoid-rhabdoid-tumors-market
• Hyperhidrosis Market: https://www.delveinsight.com/report-store/axillary-hyperhidrosis-ahh-market
• Bacterial Pyogenic Meningitis Market: https://www.delveinsight.com/report-store/bacterial-pyogenic-meningitis-market
• Becker Muscular Dystrophy Market: https://www.delveinsight.com/report-store/becker-muscular-dystrophy-market
• Bile Duct Neoplasm Market: https://www.delveinsight.com/report-store/bile-duct-cancer-market
• Bipolar Depression Market: https://www.delveinsight.com/report-store/bipolar-disorder-manic-depression-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Bradycardia Treatment Devices Market: https://www.delveinsight.com/report-store/bradycardia-treatment-devices-market
• Bronchopulmonary Dysplasia Market: https://www.delveinsight.com/report-store/bronchopulmonary-dysplasia-market
• Bunion Market: https://www.delveinsight.com/report-store/bunion-market
• Cancer Anorexia Market: https://www.delveinsight.com/report-store/cancer-anorexia-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Cardiotoxicity Market: https://www.delveinsight.com/report-store/cardiotoxicity-market
• Carpal Tunnel Syndrome Market: https://www.delveinsight.com/report-store/carpal-tunnel-release-system-market
• Catheter-related Bloodstream Infections Market: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-crbsi-market-size-analysis

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.